CRISPR Therapeutics AG CRSP

CRSP Company Overview

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9 genome-editing technology. The company operates within the biotechnology and genetic medicine industries, with a primary focus on creating therapies for serious diseases in hematology, oncology, autoimmune disorders, regenerative medicine, and rare diseases. Its business model centers on advancing proprietary gene-editing platforms into clinical-stage therapeutics, while also leveraging strategic collaborations with larger pharmaceutical and biotechnology partners.

The company’s primary revenue drivers have historically included collaboration agreements, licensing arrangements, milestone payments, and research funding tied to partnerships. CRISPR Therapeutics gained significant industry visibility through the development of exagamglogene autotemcel (exa-cel), a gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia developed with Vertex Pharmaceuticals Incorporated. Founded in 2013 by scientists including Emmanuelle Charpentier, Rodger Novak, Shaun Foy, and Daniel Anderson, the company was among the earliest enterprises built around CRISPR/Cas9 therapeutic applications and has evolved from a research-stage platform company into a commercial-stage biotechnology organization with approved therapeutic products in certain markets.